Partial irradiation of the lung

Seminars in Radiation Oncology

Volumn 11, Issue 3, 2001, Pages 247-258

  Seppenwoolde, Yvette ^a   Lebesque, Joos V ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE SULFATE;

BIOLOGICAL MODEL; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CORRELATION FUNCTION; DOSE RESPONSE; HUMAN; LUNG FUNCTION; LUNG INJURY; LUNG NON SMALL CELL CANCER; LUNG VOLUME; PARTIAL BODY RADIATION; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIATION PNEUMONIA; RADIATION RESPONSE; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0034959465     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1053/srao.2001.23482     Document Type: Article

References (70)

1. Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients
2. The pulmonary effects of thoracic irradiation
3. Severe radiation injuries of the lung
4. Time course of radiological lung density changes after postmastectomy radiotherapy
5. Radiation pneumonitis following large single dose irradiation: A re-evaluation based on absolute dose to lung
6. Irradiation of the lungs as an adjuvant therapy in the treatment of osteosarcoma of the limbs. An E.O.R.T.G. randomized study
7. An analysis of 40 cases treated by total thoracic irradiation
8. Elective whole lung irradiation in the treatment of osteogenic sarcoma
9. Quantitative clinical radiobiology of early and late lung reactions
10. Alpha/beta value and the importance of size of dose per fraction for late complications in the supraglottic larynx
11. Further comments on dose-time-fractionation considerations for lung damage
12. Radiation-induced lung damage: Dose-time-fractionation considerations
13. Radiation-induced lung damage after thoracic irradiation for Hodgkin's disease: The role of fractionation
14. Lung damage in mice from cyclophosphamide and thoracic irradiation: The effect of timing
15. Effect of cancer chemotherapeutic drugs on radiation-induced lung damage in mice
16. Tolerance of radiotherapy combined with adjuvant chemotherapy in breast cancer
17. Toxicity of a combination of ABVD chemotherapy and mediastinal irradiation for Hodgkin's disease patients with massive initial mediastinal involvement
18. Late cardiopulmonary toxicity after treatment for Hodgkin's disease
19. Late cardiac, thyroid, and pulmonary sequelae of mantle radiotherapy for Hodgkin's disease
20. Cardiopulmonary toxicity after three courses of ABVD and mediastinal irradiation in favorable Hodgkin's disease
21. Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patients with greater than or equal to 10 positive axillary lymph nodes
22. The effect of pulmonary function of local and loco-regional irradiation for breast cancer
23. Prediction of overall pulmonary function loss in relation to the 3-D dose distribution for patients with breast cancer and malignant lymphoma
24. Radiotherapy-related lung fibrosis enhanced by tamoxifen
25. The effects of cigarette smoking and smoking cessation on the carbon monoxide diffusing capacity of the lung in asymptomatic subjects
26. Acute effect of cigarette smoking on the carbon monoxide diffusing capacity of the lung
27. Effects of smoking and irradiated volume on inflammatory response in the lung of irradiated breast cancer patients evaluated with bronchoalveolar lavage
28. Smoking: The influence of carboxyhemoglobin (HbCO) on tumor oxygenation and response to radiation
29. Radiation-induced increase in hyaluronan and fibronectin in bronchoalveolar lavage fluid from breast cancer patients is suppressed by smoking
30. Tobacco smoke exposure suppresses radiation-induced inflammation in the lung: A study of bronchoalveolar lavage and ultrastructural morphology in the rat
31. Does smoking protect against radiation-induced pneumonitis?
32. Influence of age and duration of follow-up on lung function after combined chemotherapy for Hodgkin's disease
33. Radiation pneumonitis after breast cancer irradiation: Analysis of the complication probability using the relative seriality model
34. Plasma transforming growth factor beta 1 as a predictor of radiation pneumonitis
35. TGF-beta, radiation-induced pulmonary injury and lung cancer
36. Acute radiation-induced pulmonary damage: A clinical study on the response to fractionated radiation therapy
37. Quantitative effect of combined chemotherapy and fractionated radiotherapy on the incidence of radiation-induced lung damage: A prospective clinical study
38. Automatic three-dimensional matching of CT-SPECT and CT-CT to localize lung damage after radiotherapy
39. Quantifying local lung perfusion and ventilation using correlated SPECT and CT data
40. The effect of patient-specific factors on radiation-induced regional lung injury
41. Dose-effect relations for local functional and structural changes of the lung after irradiation for malignant lymphoma
42. Quantification of radiation-induced regional lung injury with perfusion imaging
43. Radiation dose-effect relations and local recovery in perfusion for patients with non-small cell lung cancer
44. The role of three dimensional functional lung imaging in radiation treatment planning: The functional dose-volume histogram
45. Tolerance of normal tissue to therapeutic irradiation
46. Fitting of normal tissue tolerance data to an analytic function
47. Complication probability as assessed from dose-volume histograms
48. Calculation of complication probability factors for non-uniform normal tissue irradiation: The effective volume method
49. Dose-volume histogram and 3-D treatment planning evaluation of patients with pneumonitis
50. Physical and biological predictors of changes in whole-lung function following thoracic irradiation
51. Confirmation of dose-volume histograms and normal tissue complication probability calculations to predict pulmonary complications after radiotherapy for lung cancer
52. Estimation of pneumonitis risk in three-dimensional treatment planning using dose-volume histogram analysis
53. Tumour and normal tissue responses to fractionated non-uniform dose delivery
54. Probability of radiation-induced complications for normal tissues with parallel architecture subject to non-uniform irradiation
55. Modeling of normal tissue response to radiation: The critical volume model
56. Probability of radiation-induced complications in normal tissues with parallel architecture under conditions of uniform whole or partial organ irradiation
57. Evaluation of two dose-volume histogram reduction models for the prediction of radiation pneumonitis
58. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC)
59. Use of Veff and iso-NTCP in the implementation of dose escalation protocols
60. Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer
61. Radiation pneumonitis as a function of mean lung dose: An analysis of pooled data of 540 patients
62. Reporting and analyzing dose distributions: A concept of equivalent uniform dose
63. Clinically relevant optimization of 3-D conformal treatments
64. Predicting overall lung function loss based on clinically determined local dose-effect relations and the full 3-dimensional dose distribution
65. A generalized concept of Equivalent Uniform Dose (EUD)
66. Recovery of overall and local lung function loss 18 months after irradiation for malignant lymphoma
67. Effect of radiotherapy and chemotherapy on pulmonary function after treatment for breast cancer and lymphoma: A follow-up study
68. Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer
69. Modelling of parotic salivary gland function following irradiation of head and neck cancer
70. Determination of model parameters for description of radiation induced liver disease